This article first appeared in
New Dawn Special Issue Volume 12, Number 6, 2018.
© Brett Lothian
Inside the Psychedelic Mind: The New Frontier for Consciousness Studies, Innovative Therapies, Micro-dosing & Creativity.
“LSD is a psychedelic drug that occasionally causes
psychotic behaviour in people who have NOT taken it.” ~ Timothy Leary, Ph.D.
Psychedelic plants and drugs have been a controversial
subject ever since the late 1960’s and the hippy flower power movement, despite
having a history of human use going back thousands upon thousands of years all
over the world. In recent times, attitudes have begun to change in the way in
which we see psychedelics and their potential applications for humanity, with
new scientific research moving ahead in leaps and bounds after the long halt in
official research caused by the American led ‘war on drugs.’ Today, we understand
far more about how psychedelics actually work in the brain and how they affect
our consciousness, often in very profound ways and are as such we are now on
the verge of once again having psychedelic plants and drugs legalized and used
in modern medicine. Interestingly, the ways in which psychedelics are being
used and the reasons for doing so are also changing and evolving, opening up
whole new vistas in the psychedelic field, modern medicine and even the very
way in which we think about and solve the many and varied problems that are
affecting our world today.
Firstly, if we want to truly understand the psychedelic
experience and how it affects our minds and consciousness, we have to understand
exactly what is happening in the brain when we take these substances. Research
has shown that the classic psychedelic compounds primarily act upon the brain's
neural cortex, where they activate specific receptors called 5-HT2A receptors
that are usually activated by serotonin. "In order to function, (the
cortex is) integrating different signals, for example glutamate signals and
serotonin signals," said neuroscientist Stuart Sealfon of Mount Sinai
School of Medicine in New York, "and what hallucinogens must be doing is
they are disrupting this process so that sensory perception is altered by
them." However, not all compounds that activate these receptors lead to
psychedelic experiences. In the past, scientists perceived neurotransmitter
receptors such as the 5-HT2A receptor as being like "locks and keys,"
in which certain compounds would fit into a specific receptor as a key fits
into a lock. The receptor would then turn on and signal to the other molecules
in the cell. But this has been found to not be the case for psychedelics.
Research by Sealfon and his colleagues published in the journal Neuron revealed
that the 5-HT2A receptor has in fact more than one "on" position. "When
a non-hallucinogen activates the receptor, it causes one pattern of signaling
of the cells in the brain that is not hallucinogenic," Sealfon told
LiveScience. "When a hallucinogen turns on this receptor, the receptor we
infer must go into a different position and that leads to a different pattern
in responses in the cell and is what makes the hallucinogen have its unique
effect."
In 1954, the author and philosopher Aldous Huxley in his
seminal work The Doors of Perception proposed that the brain in its ordinary
state, acts as a kind of ‘reducing valve,’ restricting conscious awareness. “The
function of the brain and nervous system is in the main eliminative”, he
observed, “leaving only that very small and special selection which is likely
to be practically useful”. He theorized whilst under the influence of the
psychedelic compound Mescaline (that is found in San Pedro and Peyote cacti)
that the compound allowed him to see that what we normally call “reality” is in
fact the product of a massive filtering out of reality, a systematic closing of
the doors, leaving only the programs of measurement and utility, reality as it
would necessarily appear “to an animal obsessed with survival.” Tom Wolfe in
his classic book, The Electric Kool-Aid Acid Test, explained it as follows, “Aldous
Huxley compared the brain to a ‘reducing valve.’ In ordinary perception, the
senses send an overwhelming flood of information to the brain, which the brain
then filters down to a trickle it can manage for the purpose of survival in a
highly competitive world. Man has become so rational, so utilitarian, that the
trickle becomes most pale and thin. It is efficient, for mere survival, but it
screens out the most wondrous part of man's potential experience without his
even knowing it. We're shut off from our own world.”
Huxley proposed that when we are under the influence of a
psychedelic substance, this ‘reducing valve’ is opened up and that we are able
to consciously perceive a much richer, more meaningful and wondrous existence.
Modern research is showing us now that Huxley was in fact right all along. A
2016 study headed by lead researcher David Nutt, the UK government’s former
drugs advisor and professor of neuropsychopharmacology at Imperial College
London, showed the profound changes that LSD has upon the brain and
consciousness, changes that dramatically altered the activity and connectivity
across the human brain. Brain scans revealed in those studied that they
experienced images through information drawn from many parts of their brains,
not just the visual cortex that normally processes visual information. Using
three different brain imaging techniques, named arterial spin labelling,
resting state MRI and magnetoencephalography, the scientists measured blood
flow, functional connections within and between brain networks, and brainwaves
in the volunteers both on and off of the psychedelic compound. Under the
influence of LSD, entire regions of the brain that are normally cut off from
each other, instead worked together to produce the altered state of perception
and consciousness. “The drug can be seen as reversing the more restricted
thinking we develop from infancy to adulthood,” said Nutt, whose study was
published in the journal Proceedings of the National Academy of Sciences.
Further images also showed that the brain regions that
usually form a network in ordinary consciousness, became more separated as
those studied experienced “feelings of oneness with the world and a loss of
personal identity” that is often called ego dissolution or as it known in
traditional shamanism, as ego death. “You don’t recognize yourself as a
separate being from the universe. It feels, in a way, like transferring the
consciousness from within your own body to the outside world; the focus is in
the objects that surround you rather than outside.” Scans revealed a loss of
connections between parts of the brain called the parahippocampus and another
region known as the retrosplenial cortex. “This experience is sometimes framed
in a religious or spiritual way, and seems to be associated with improvements
in wellbeing after the drug’s effects have subsided,” Carhart-Harris said. Importantly,
researchers noted in this study that the regions in the brain involved with
introspection (thinking about one’s self) and the way one perceives the outside
world, communicated with each other much more intensely under the influence of
LSD. “When we measured the brains of subjects who were really blown away by
LSD, who had a really strong feeling of ego dissolution, they were also the
ones who had the strongest increase in communication between the network
regions in charge of introspection and the network regions in charge of
perceiving the external world.”
Another researcher involved in the study, Robin
Carhart-Harris, said that whilst under the influence of LSD, the brain scans
suggested that the volunteers were “seeing with their eyes shut, we saw many
more areas of the brain than normal were contributing to visual processing
under LSD, even though volunteers’ eyes were closed.” The more pronounced the
effect in the brain, the more intense people rated their psychedelic visions.
Under the influence of LSD, brain networks that deal with vision, attention,
movement and hearing became far more connected, leading to what looked like a
“more unified brain”, he said. David Nutt, went on to say that neuroscientists
had waited 50 years for this moment. “This is to neuroscience what the Higgs
boson was to particle physics,” he said. “We didn’t know how these profound
effects were produced. It was too difficult to do. Scientists were either
scared or couldn’t be bothered to overcome the enormous hurdles to get this
done.” Amanda Feilding, director of the Beckley Foundation, said in response to
this study that “we are finally unveiling the brain mechanisms underlying the
potential of LSD, not only to heal, but also to deepen our understanding of
consciousness itself.”
Furthering this important work, the researchers at Imperial
College London as well as researchers from the University of Sussex, measured
the activity of neurons in people’s brains under the influence of the
psychedelics LSD, ketamine and psilocybin (the active ingredient in magic
mushrooms). The brain scans revealed the first scientific evidence for what
appears to be a heightened state of consciousness. The volunteers studied were
found to have more random brain activity than normal while under the influence
of these psychedelics. The shift in brain activity came with a plethora of
peculiar sensations that the participants described as ranging from floating
and finding inner peace, to distortions in time and a conviction that the self
was disintegrating. “What we find is that under each of these psychedelic
compounds, this specific measure of global conscious level goes up, so it moves
in the other direction. The neural activity becomes more unpredictable,” said
Anil Seth, a professor of neuroscience at the University of Sussex. “Until now,
we’ve only ever seen decreases compared to the baseline of the normal waking
state.” The scans found the most notable effects in parts of the brain that are
known to be important for perceptions, rather than other roles such as language
and movement. “I think people would have the intuitive idea that their
experience on psychedelic compounds is a bit more random, a bit less
constrained, that there’s a mixing of the senses, and all kinds of connections
that are experienced between things that are previously unconnected,” Seth
said.
“We see an increase in the diversity of signals from the
brain,” said Seth. “The brain is more complex in its activity.” Previous
studies have demonstrated that people in a state of wakefulness or ordinary
consciousness, have more diverse patterns of brain activity than people who are
asleep. The researchers have found that people who have taken psychedelics show
an even greater amount of diversity, in fact the highest level of diversity ever
measured. Robin Carhart-Harris, who also took part in this study, said the sudden
increase in randomness and diversity in brain activity appears to show a deeper
and richer state of consciousness. “People tend to associate phrases like ‘a
higher state of consciousness’ with hippy speak and mystical nonsense. This is
potentially the beginning of the demystification, showing its physiological and
biological underpinnings,” he said. “Maybe this is a neural signature of the
mind opening.” Beyond confirming what shaman all over the world have known for
millennia and what the hippies learned back in the 60’s, the research could
help scientists to finally understand exactly what types of neural activity
correspond to the different levels of consciousness in humans.
It is also hoped that by understanding how different people
respond to taking psychedelics, that doctors can more accurately predict which
patients might benefit from taking psychedelics to treat mental disorders, such
as depression, anxiety and post-traumatic stress. “The evidence is becoming
clear that there is a clinical efficacy with these drugs,” said Seth. “I think
there’s an awful lot of potential here, if you suddenly see things in a
different way, it could give your outlook a jolt that existing antidepressants
can’t because they work on the routine, wakeful state.” In fact, more and more
research is confirming this to be exactly the case. In another study produced
by David Nutt, Robin Carhart-Harris and others, the psychedelic compound
psilocybin has been shown to be effective in alleviating symptoms in otherwise
treatment resistant depression. There had been numerous studies suggesting
psychedelics could play a role in treating depression by acting as a sort of
"lubricant for the mind," allowing people to break destructive cycles
of depressive symptoms, but the precise effect on brain activity was not yet known.
The team at Imperial College London performed fMRI brain scans before treatment
with psilocybin and then the day after, once the psychedelic effects had worn
off. The study showed psilocybin affected two important areas of the human
brain, the amygdala, which is largely involved in how we process emotions such
as fear and anxiety, became less active. The greater the reduction, the greater
the improvement in the reported symptoms. Also effected was the default-mode
network, a collaboration of different brain regions which became more stable
after taking psilocybin.
Dr Carhart-Harris, said that the depressed brain was being
"clammed up" and that the psychedelic experience had "reset"
it. He told the BBC News website: "Patients were very ready to use this
analogy. Without any priming they would say, 'I've been reset, reborn,
rebooted', and one patient said his brain had been defragged and cleaned up,"
with the effects lasting for weeks and even months. Prof Mitul Mehta, from the
Institute of Psychiatry at King's College London, said: "What is
impressive about these preliminary findings is that brain changes occurred in
the networks we know are involved in depression, after just a single dose of
psilocybin. This provides a clear rationale to now look at the longer-term
mechanisms in controlled studies." Carhart-Harris believes that the use of
psychedelics effectively "heats up" the mind from its rigidity,
enabling people to overcome ingrained, self-destructive patterns of thinking.
With support from a qualified therapist, those who have undergone the treatment
can then "recalibrate in a healthier way, so you're revising your beliefs
and assumptions and addictions", Carhart-Harris says. Furthermore and
importantly, Dr Carhart-Harris acknowledges that psychedelics are never going
to be for everyone. "Some people won't want to go to the depths of their
soul or face demons or traumas they've experienced, or dark aspects of the
human condition that are there in all of us," he said.
Another interesting psychedelic compound that is showing
remarkable effectiveness in alleviating the symptoms of treatment resistant
depression is Ketamine (commonly known as ‘Special K’), that has in recent
times come to be thought of as one of the biggest breakthroughs in the psychiatric
treatments for severe depression. In as little time as half an hour, it has
been shown to banish severe depression symptoms and even suicidal thoughts in the
patients tested, often after all other psychiatric options have been exhausted
and the effects can last for weeks. A recent study published in the journal
Nature, has been able to elucidate just how ketamine acts in the brain to
achieve its impressive results. A team of doctors and neuroscientists from
Zhejiang University in China have shown that ketamine switches off an erratic
burst of electrical impulses firing in neurons in the brain region known as the
lateral habenula. “The lateral habenula is like the ‘anti-reward center’ in the
brain,” the study’s lead author Professor Hailan Hu told The Independent. When
the lateral habenula is firing erratic bursts of electrical impulses, it acts
against the areas where key mood-boosting neurotransmitters, dopamine and
serotonin are produced by the brain. “The lateral habenula inhibits both of
those reward centers,” she added. “So when it goes into the bursting mode, the
suppression becomes much stronger, it’s like a machine gun compared to a single
shot.” Whilst in the last decade or so, the lateral habenula has become thought
of as a major driver for the negative moods involved in depression, the reasons
for this have been difficult to exhibit.
Professor Hu’s team had been examining this region of the
brain, using rats to study the differences in depressed and normal brains and
had identified certain patterns of irregular electrical activity that they
thought could be playing a role. “In previous experiments we had delivered
ketamine generally into the body, so you wouldn’t know which brain region was
being affected,” Professor Hu said. “But in this study we injected it directly
into the lateral habenula and we were surprised to find that just affecting
this very localized area was sufficient to have this very rapid antidepressant
effect.” The findings in rats were akin to the extremely rapid relief of
symptoms that can be seen in humans and suggests that ketamine’s remarkable
effects could be largely derived from this one area, as no other parts of the
brain were being treated. With further experimentation, the researchers were
able to show that a group of receptors (NMDARs) are causing these signals and
are effectively blocked by ketamine. Also published in the journal Nature, an
analysis of the findings by Dr Paul Kenny, professor of neuroscience at the
Icahn School of Medicine at Mount Sinai in New York, said that “ketamine is
currently in clinical trials for the treatment of major depressive disorder
with imminent risk of suicide, but the mechanisms by which ketamine acts have
been a puzzle to scientists. These findings suggest that the therapeutic
actions of ketamine might relate, at least in part, to its ability to block
burst firing in the lateral habenula, this knowledge might facilitate the
development of next-generation ketamine-related antidepressants that specifically
target lateral habenula activity.”
A study released in June of this year has shed even more
light on the impressive effects of ketamine in the brain and how it helps to
treat mental illness. Importantly, the researchers tested a number of psychedelic
compounds for comparison and the results were truly astounding. "These are
some of the most powerful compounds known to affect brain function, it's very
obvious to me that we should understand how they work," said senior author
David E. Olson, assistant professor in the Department of Chemistry and the
Department of Biochemistry & Molecular Medicine at the University of
California, Davis. “One of the hallmarks of depression is that the neurites in
the prefrontal cortex – a key brain region that regulates emotion, mood, and
anxiety – those neurites tend to shrivel up,” said Olson. It had previously
been believed that depression stems from imbalanced brain chemistry, but recent
studies have shown that depression manifests as structural changes in brain
circuitry or as an atrophy in parts of the brain. This does not mean that the
neurons die off in those suffering mental illness, but that the neurites
retract. Neurites are the sections of a neuron that bridge the gap between two
neurons at the synapse to enable communication. These brain changes are also
apparent in the cases of people suffering anxiety, addiction, and
post-traumatic stress disorder. In the study, Olson and colleagues tested
psychedelics from the amphetamine, tryptamine, tropane and ergoline drug
classes. In both test tube and animal experiments, the psychedelics displayed
functional and structural changes that were similar to those produced by
ketamine in cortical neurons. Psychedelics increased both the density of
dendritic spines and the density of synapses. Some psychedelics tested,
including LSD, proved to be even more potent and effective than ketamine in
promoting neurite growth.
What this basically means is that psychedelic compounds
literally have the power to rewire damaged brains, confirming the intuitive
findings of the people who say that psychedelics have “reset, rebooted or
defragged” their minds. The researchers conducted their experiments in both
vertebrates and invertebrates, showing that psychedelics produced similar
effects across species. This demonstrates that the biological mechanisms
involved with psychedelic effects have remained the same across millions of
years of evolution and that psychedelics will most likely have the same brain
growth or neural plasticity effects in humans. Olson and his team also set out
to test exactly how these psychedelics produced neural plasticity. The
researchers explored which biological pathways psychedelics activate to promote
neural growth. Ketamine's neural plasticity effect was previously discovered to
be largely dependent upon a protein named brain-derived neurotrophic factor
(BDNF). When BDNF signaling was blocked, interestingly the psychedelics lost
their capability to promote neurite growth. BDNF binds to a receptor, named TrkB
that is part of a signaling pathway which includes mTOR that is known to play a
major part in producing the proteins necessary for the creation of new synapses.
When mTOR was also blocked, it also completely inhibited the psychedelics'
ability to promote neurite growth. Intriguingly the one psychedelic tested that
did not promote neural plasticity was ibogaine (the active ingredient in iboga)
but that a metabolite of ibogaine, namely noribogaine did, which explains
iboga’s effectiveness.
Unfortunately space in this article does not permit me to examine
all of the interesting work that is being done in regards to psychedelics with
depression, anxiety, PTSD and addiction as there has been literally a flood of
recent studies that are all saying the same things, that they work and are far
more effective and longer lasting (even at a single dose) than anything that is
currently being prescribed in the treatments of these debilitating mental
illnesses. A number of psychedelic compounds are presently being fast tracked
through the clinical trial phases of human testing and will soon be available
to doctors to help treat these diseases. I encourage our intrepid New Dawn
readers to please do research the studies cited in the references for this
article and the veritable compendium of scientific literature and anecdotal
evidence that is freely available on the internet, as well my previous article for
New Dawn on psychedelic research,
Sacred Plant Healing: Shamanic Plant Medicine and the New Science, which appeared in the special issue volume 10, number 5
and is now freely available on my Tricho Serious Ethnobotany blog, for more in
depth information. As our societies mental health issues, addictions and
suicide rates continue to grow at an alarming rate, this extremely important
information needs to be disseminated as widely as possible and brought to the
attention of the wider public, and of course our policy and law makers.
Other debilitating mental scourges that are ever increasing
in our modern society such as Dementia, Alzheimer’s and Down syndrome may also
benefit from the use of psychedelic substances. In a study released by the D'Or
Institute for Research and Education, it was discovered that harmine which is
present in the popular psychedelic drink ayahuasca and which has been used by
psychonauts to potentiate other psychedelics, inhibits what is known as DYRKIA
which is located on chromosome 21 and is overly activated in patients suffering
from Down syndrome and Alzheimer’s disease. Also it was ascertained that the
beta-carboline harmine also led to an increase of 70% in the proliferation of
human neural progenitor cells. "It has been shown in rodents that antidepressant
medication acts by inducing neurogenesis. So we decided to test if harmine, an
alkaloid with the highest concentration in the psychotropic plant decoction
ayahuasca, would trigger neurogenesis in human neural cells," said Vanja
Dakic, PhD student and one of the authors in the study. "Our results
demonstrate that harmine is able to generate new human neural cells, similarly
to the effects of classical antidepressant drugs, which frequently are followed
by diverse side effects. Moreover, the observation that harmine inhibits DYRK1A
in neural cells allows us to speculate about future studies to test its
potential therapeutic role over cognitive deficits observed in Down syndrome
and neurodegenerative diseases," suggests Stevens Rehen, researcher from
IDOR and ICB-UFRJ. As we already know that psychedelics can promote new neuron
growth and networks and that harmine promotes the growth of new brain cells,
whilst also inhibiting the over active DYRKIA associated with Down syndrome and
Alzheimer’s, ayahuasca could be just what the doctor ordered to help people
with neurodegenerative diseases literally regrow and rewire their damaged
brains.
A new trend that is emerging and growing in popularity with
psychedelics, particularly among the genius Silicon Valley crowd, is micro-dosing
which was first promoted by Dr. James Fadiman in his excellent book, The
Psychedelic Explorers Guide that I reviewed for New Dawn issue 164. Micro-dosing
is exactly as it sounds, taking small (non-psychedelic) amounts of these substances,
to boost creativity, cognitive function and elevate mood. Whilst numerous
studies have demonstrated a link between psychedelic use and increased
creativity, artistic expression, problem solving and overall cognitive function,
whether these substances could have the same effects in sub-perceptual or
non-psychedelic dosages had never been tested, until now. Researchers from
Leiden University in the Netherlands have released the first official study
into micro-dosing in October of this year and their findings support the
mounting anecdotal evidence that even in tiny amounts, psychedelics can have
profound impacts upon the ways in which we think. “Our results suggest that
consuming a micro-dose of truffles (magic mushrooms) allowed participants to
create more out-of-the-box alternative solutions for a problem, thus providing
preliminary support for the assumption that micro-dosing improves divergent
thinking," lead author Luisa Prochazkova explained. "Moreover, we
also observed an improvement in convergent thinking, that is, increased
performance on a task that requires the convergence on one single correct or
best solution." The authors of the study called this “changes in fluid
intelligence” and noted that the participants created solutions that were more
original and flexible than they had before micro-dosing. More studies are
currently underway into the effects of micro-dosing with other psychedelic
compounds, which will in all likelihood produce similar results.
Whilst the use of psychedelics has long been advocated for
improving intelligence and creativity by such mental luminaries as Dr. Francis
Crick who discovered the double helix nature of DNA, Apple computers founder
Steve Jobs and Microsoft founder Bill Gates, whether psychedelics actually changed
what we think was largely
speculation. A new study released earlier this year has given us an intriguing
insight into the potential changes in just what we think through the use of
psychedelic plants and compounds. “Our findings tentatively raise the possibility
that given in this way, psilocybin may produce sustained changes in outlook and
political perspective, here in the direction of increased nature relatedness
and decreased authoritarianism,” researchers Taylor Lyons and Robin
Carhart-Harris wrote in the study. “Before I enjoyed nature, now I feel part of
it. Before I was looking at it as a thing, like TV or a painting… [But now I
see] there’s no separation or distinction, you are it,” one participant said in
the follow-up exam. “This pilot study suggests that psilocybin with
psychological support might produce lasting changes in attitudes and beliefs.
Although it would be premature to infer causality from this small study, the
possibility of drug-induced changes in belief systems seems sufficiently
intriguing and timely to deserve further investigation,” the study concluded. Could
these feelings of increased nature relatedness and anti-authoritarianism
explain the peace and love hippy counter culture revolution of the late 1960’s
and why these plants and substances were subsequently banned by the ever
increasingly authoritarian, nanny state governments of the world? I will leave
that for the reader to decide.
Perhaps the most important of all the changes in what we
think, our beliefs and our attitudes that psychedelics produce is in removing
the fear of death and the experience of the mystical. In a recent study by the Johns
Hopkins Medical School, 51 terminally ill patients were given magic mushrooms
and a remarkable 80% of them said that it had helped them to feel more
optimistic and less scared of death. Matthew W. Johnson who was involved in the
study offered that the experience produced by the mushrooms "appear
indistinct, oftentimes from religious experiences." Research conducted by
Griffiths et al. showed that the mystical experiences participants had under the
influence of psilocybin were “among the most personally meaningful and
spiritually significant of their lives” and that they were very long lasting. Charles
Grob, UCLA professor of psychiatry and pediatrics who also conducted a study
that gave psilocybin to late-stage cancer patients has said that "the
reports I got back from the subjects, from their partners, from their families
were very positive, that the experience was of great value, and it helped them
regain a sense of purpose, a sense of meaning to their life. The quality of
their lives notably improved."
As the famed mystic and inspiration for Aldous Huxley’s
greatest work, The Doors of Perception, William Blake once wrote, “If the doors
of perception were cleansed, everything would appear to man as it is, infinite.”
~*
References:
How Do Hallucinogens Work?
How Do Psychedelics Work? A Look Inside the Hallucinating
Brain
The Doors of Perception. By Aldous Huxley
The Electric Kool-Aid Acid Test. By Tom Wolfe
LSD's impact on the brain revealed in groundbreaking images
Psychedelic drugs induce 'heightened state of
consciousness', brain scans show
Psychedelic drugs push the brain to a state never seen
before
Magic mushrooms can 'reset' depressed brain
Could psychedelics transform mental health?
Psychedelic drug ayahuasca improves hard-to-treat depression
Psychedelic ayahuasca works against severe depression, study
finds
Psychedelic Drugs: LSD Changes Brain, Could Be Used for
Depression, Addiction Treatment
Ketamine nasal spray rapidly relieves depression and
suicidal thoughts, finds trial
Remarkable secrets of ketamine's antidepressant effect
unlocked by scientists
Psychedelics Promote Structural and Functional Neural
Plasticity
Psychedelic drugs promote neural plasticity in rats and
flies
LSD and magic mushrooms could heal damaged brain cells in
people suffering from depression, study shows
Does ibogaine treatment for depression help?
Psychedelics and MDMA are helping cure PTSD, addiction,
depression and anxiety
Classical hallucinogens as antidepressants? A review of
pharmacodynamics and putative clinical roles
Sacred Plant Healing: Shamanic Plant Medicine and the New
Science
A brief history of psychedelic psychiatry
Substance present in ayahuasca brew stimulates generation of
human neural cells
The Psychedelic Explorers Guide. By James Fadiman, Ph.D.
Microdosing Magic Mushrooms Could Spark Creativity And Boost
Cognitive Skills, Claims New Study
Study Says Psychedelic Mushrooms Make People More Resistant
To Authority
Dying humans are taking mushrooms to study our fear of the
unknown
'My fear of dying was gone': Former cancer patient says
psychedelic drugs helped him cope with end of life anxiety
What Is So Important About The Mystical Experience?
The most convincing argument for legalizing LSD, shrooms,
and other psychedelics
